Cochrane · systematic review · CD011346
Aflibercept for neovascular age‐related macular degeneration
Sarwar, S, Clearfield, E, Soliman, MK, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 33.3%High 4 · 66.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: people with age‐related macular degeneration
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mean change in BCVA in ETDRS letters at 1 year (number of letters) | no estimate extracted | 2 studies · 2412 participants | High |
Gain of ≥ 15 letters of BVCA at 1 year | RR 0.97 [0.85, 1.11] | 2 studies · 2412 participants | High |
Absence of fluid on optical coherence tomography (OCT) at 1 year | RR 1.06 [0.98, 1.14] | 2 studies · 2291 participants | High |
Quality‐of‐life measures at 1 year (National Eye Institute‐Visual Function Questionnaire [NEI‐VFQ]) | no estimate extracted | 2 studies · 2412 participants | High |
Adverse events ‐ serious systemic events at 1 year | RR 0.99 [0.79, 1.25] | 2 studies · 2419 participants | Moderate |
Adverse events ‐ serious ocular events at 1 year | RR 0.62 [0.36, 1.07] | 2 studies · 2419 participants | Moderate |